Pharma Marketing and Doctors

How drug companies promote brands to doctors, why this can raise costs for patients, and India's rules on gifts and incentives.

Most medicines are chosen by doctors, not patients. So drug companies focus marketing on doctors.

How it works

Medical representatives visit doctors to promote brands.
Free samples.
Conferences and sponsored events.
In some cases, gifts, travel or other incentives.

In India’s branded generics market, many brands of the same molecule compete, so marketing to doctors strongly influences sales.

The concern

When doctors receive benefits from companies, they may prescribe more expensive brands or unnecessary medicines, raising costs for patients who mostly pay out of pocket. This is a principal-agent problem: the doctor acts for the patient but may have other incentives.

India’s rules

The Indian Medical Council regulations barred doctors from accepting gifts and travel from pharma companies.
The Uniform Code for Pharmaceutical Marketing Practices, updated in 2024, bans companies from offering gifts, travel and cash to doctors and their families, with some exceptions, and requires disclosure of spending on events.

Enforcement has been debated, as the code relies largely on industry associations.

Evidence

Studies in the US, where payments to doctors are published, found that doctors who received payments from drug companies tended to prescribe more of those companies’ drugs.

The sponsored trip

A doctor attends a conference sponsored by a drug company at a luxury resort. Later, he prescribes that company's more expensive brand. Rules banning such incentives aim to break this link.

Thinking prescriptions depend only on medical need

Marketing and incentives can influence which brands doctors prescribe.

Key takeaways

Drug companies market mainly to doctors.
Incentives can push doctors toward costlier brands.
India's 2024 marketing code bans gifts, travel and cash to doctors.
US data link company payments to prescribing patterns.